Wells Fargo
BDTX icon

Wells Fargo’s Black Diamond Therapeutics BDTX Stock Holding History

Wells Fargo’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$73.2K Buy
+39,555
New +$96.8K ﹤0.01% 5614
2025
Q3 		– Sell
-335
Closed -$831 – 7096
2025
Q2 		$831 Sell
335
-20,237
-98% -$39K ﹤0.01% 6327
2025
Q1 		$31.9K Buy
20,572
+453
+2% +$950 ﹤0.01% 5544
2024
Q4 		$43.1K Buy
20,119
+5,932
+42% +$17K ﹤0.01% 5534
2024
Q3 		$61.7K Buy
14,187
+469
+3% +$2.55K ﹤0.01% 5266
2024
Q2 		$63.9K Buy
13,718
+13,439
+4,817% +$72.1K ﹤0.01% 5192
2024
Q1 		$1.42K Buy
279
+5
+2% +$20 ﹤0.01% 6085
2023
Q4 		$770 Sell
274
-86
-24% -$202 ﹤0.01% 6289
2023
Q3 		$1.03K Buy
360
+113
+46% +$416 ﹤0.01% 6193
2023
Q2 		$1.25K Sell
247
-394
-61% -$805 ﹤0.01% 6281
2023
Q1 		$1.21K Buy
641
+402
+168% +$924 ﹤0.01% 6324
2022
Q4 		$430 Sell
239
-496
-67% -$893 ﹤0.01% 6425
2022
Q3 		$1K Sell
735
-16
-2% -$49 ﹤0.01% 6276
2022
Q2 		$1K Sell
751
-1,179
-61% -$2.74K ﹤0.01% 6462
2022
Q1 		$6K Sell
1,930
-8,075
-81% -$29.5K ﹤0.01% 6415
2021
Q4 		$53K Sell
10,005
-3,663
-27% -$25.6K ﹤0.01% 5944
2021
Q3 		$115K Buy
13,668
+289
+2% +$2.85K ﹤0.01% 5336
2021
Q2 		$163K Sell
13,379
-656,475
-98% -$13M ﹤0.01% 5113
2021
Q1 		$16.3M Buy
669,854
+6,221
+0.9% +$168K ﹤0.01% 1826
2020
Q4 		$21.3M Buy
663,633
+201,246
+44% +$6.61M 0.01% 1516
2020
Q3 		$14M Buy
462,387
+177,855
+63% +$5.41M ﹤0.01% 1666
2020
Q2 		$12M Buy
284,532
+266,336
+1,464% +$9.8M ﹤0.01% 1713
2020
Q1 		$454K Buy
+18,196
New +$554K ﹤0.01% 4108

Other funds holding BDTX

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Wells Fargo's BDTX Position: Q2 2026 in Review

Wells Fargo opened a new position in Black Diamond Therapeutics (BDTX) in Q2 2026: 39,555 shares worth $73.2K. The stake represents ﹤0.01% of the portfolio and ranks #5614 among its holdings. This is a return to the name: Wells Fargo previously reported a position in BDTX as recently as Q2 2025.

Wells Fargo first reported a position in BDTX in Q1 2020 and has held it in 23 quarters since. The position peaked at $21.3M in Q4 2020. 96 funds tracked by Wall St. Rank hold BDTX as of Q2 2026.

  • Wells Fargo held 39,555 shares of Black Diamond Therapeutics worth $73.2K as of Q2 2026.
  • Black Diamond Therapeutics was a new Wells Fargo position in Q2 2026.
  • Black Diamond Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #5614 holding.
  • Wells Fargo first reported a position in Black Diamond Therapeutics in Q1 2020 and has held it in 23 quarters since.
  • Wells Fargo's Black Diamond Therapeutics position peaked at $21.3M in Q4 2020.
  • 96 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.